PineaminПинеамин
What is it?
A preparation of water-soluble polypeptide fractions extracted from bovine pineal glands, manufactured by Geropharm with glycine as a stabilizer. It is a tissue-derived mixture, not a single defined peptide or melatonin itself.
Identity / background source ↗
Research context
A bovine pineal-gland polypeptide mixture investigated in menopausal symptoms and age-related melatonin physiology. It is distinct from Pinealon (EDR), synthetic Epitalon (AEDG), and the separately studied extract Epithalamin.
Selected study findings
randomized trial · 2016
Study of this preparation · Original clinical report
120 postmenopausal women aged 45–60; placebo 30, one-course group 30, two-course group 60
The multicenter double-blind trial reported improvement in modified Kupperman symptom scores versus placebo, principally neurovegetative symptoms. The two-course group retained a reported difference at day 180. Nineteen participants withdrew; 101 comprised the per-protocol population.
Limit: The report recorded 22 adverse events; normal laboratory measures do not prove overall safety. Allocation concealment, missing-data handling and clinical importance of the score differences need detailed appraisal. Related 2015/2016 reports may describe the same cohort; do not count them as independent trials. Menopause symptom findings do not establish general insomnia treatment or longevity effects.
Recent tendencies in the prevention and treatment of menopausal syndrome ↗observational · 2017
Study of this preparation · Original human biomarker report
55 older patients with reduced pineal melatonin function
The Russian abstract reports a 1.9-fold increase in nighttime urinary 6-sulfatoxymelatonin compared with the pretreatment value. This is a melatonin-metabolite finding, not a measured improvement in sleep architecture.
Limit: Randomization and a concurrent placebo group are not established by the abstract. The comparison with Epithalamin refers to earlier findings, not an established head-to-head trial. No demonstrated REM-sleep, lifespan or healthy-person performance benefit follows from this biomarker. Author affiliations include Geropharm; independent confirmation requires assessment.
Pineamin increased pineal melatonin synthesis in elderly people ↗Selected findings, not a systematic review or a treatment recommendation. Combination and related-preparation results cannot be attributed to this compound alone. See each source for access status and remaining limitations.
- Compound class
- Pineal tissue-derived polypeptide preparation
- Research collection
- Peptide bioregulation · editorial grouping
- Research institutions
- No institutional affiliation recorded
- Source review
- Review dates and the material assessed are listed with each publication below.
Evidence assessment
- Human research
- —Placebo-controlled menopausal-symptom trial and an older-adult biomarker report
- Study methods
- —Clinical symptom scales and urinary melatonin-metabolite measurement address different questions
- Independent replication
- —Independent replication and overlap between menopause publications require assessment
- Source access
- —Publisher trial report, PubMed abstract and manufacturer identity information
- Safety evidence
- —Short clinical follow-up does not establish uncommon harms or long-term safety
These fields describe different aspects of the evidence. A missing record does not mean that no research exists.
Linked sources
Explore the research map and unresolved leads ↗
Browse bibliography & PDFs ↗